ESMO26: Amgen’s Imdelltra posts win in first-line SCLC maintenance setting
In the DeLLphi-305 trial, the Imdelltra/Imfinzi combination extended mOS to 21.1 months vs. 12.7 months with Imfinzi alone.
Comment & Opinion
ESMO26: An $8.4bn bispecific ADC doubles PFS in HR+/HER2- breast cancer
ESMO26: Oral cell cycle inhibitors place Cyclin E1 as new target in PROC
New evidence shows depression linked to circadian rhythm
Influenza mortality in hospitalised patients affected by vaccination
Covid-19 and international aid cuts disrupt tuberculosis care in South Africa
ESMO26: HUTCHMED and AstraZeneca share positive outlook on NSCLC trials
Where options run out, BRIA-ABC bets on survival in metastatic breast cancer
